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Abstract: Brain metastases (BM) from extracranial cancer are associated with significant
morbidity and mortality. Local treatment options are surgical resection, stereotactic
radiotherapy, e.g., radiosurgery or fractionated external beam radiotherapy.
Furthermore, systemic treatment options for control of intracranial disease are
increasingly utilized. Diagnosis, treatment planning and follow-up is most often based
on contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging
modalities have limitations, particularly in terms of the diagnosis of post-therapeutic
reactive changes as well as the assessment of treatment response. Molecular imaging
techniques such as positron emission tomography (PET) characterize specific
metabolic and cellular features of metastatic cancer which may provide clinically
relevant information beyond anatomic MRI. Here, the RANO working group provide
recommendations for the use of PET imaging in the clinical management of patients
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Dear Professor Wen, 
 
we would like to re-submit the revised manuscript (third revision) 
entitled “PET Imaging in Patients with Brain Metastasis - Report of 
the RANO/PET Group“ for publication as review article in “Neuro-
Oncology”. 
 
We are grateful for the helpful comments of the reviewer and have 
studied the remarks carefully. The revision covers all suggestions and 
questions. In detail, we would like to respond to the reviewer’s 
recommendations as indicated in the reply letter (changes in the 
manuscript are highlighted in red). A native speaker who performed an 
extensive revision of language, grammar and shortening of various 
paragraphes has now been added as a new co-author. 
 
We hope that the manuscript in the present form is now acceptable for 
publication in “Neuro-Oncology”. The manuscript or any part of it has 
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Reviewer #3  
 
Comment: The introduction is still too long and in some paragraphs is repetitive. 
Although the writing has improved, long, rambling, and confusing sentences persist 
throughout the manuscript. 
 
Reply: The whole manuscript has now been revised and shortened by two native 
speakers. The word count could be further reduced by approx. 150 words. 
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Brain metastases (BM) from extracranial cancer are associated with significant 
morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, 
including radiosurgery or fractionated external beam radiotherapy, and surgical 
resection. The use of systemic treatment for intracranial disease control also is 
improving.  BM diagnosis, treatment planning and follow-up is most often based on 
contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging 
modalities including standard MRI have limitations in accurately characterizing post-
therapeutic reactive changes and treatment response. Molecular imaging techniques 
such as positron emission tomography (PET) characterize specific metabolic and 
cellular features of metastases, potentially providing clinically relevant information 
supplementing anatomic MRI. Here, the RANO working group provides 
recommendations for the use of PET imaging in the clinical management of patients 
with BM based on evidence from studies validated by histology and/or clinical outcome. 
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Brain metastases (BM) often occur in advanced malignancies but may also be an initial 
disease manifestation in, for example, cancer of unknown primary (CUP). BM derive 
most frequently from lung cancer (40-50% of all BM), breast cancer (15-20%), 
melanoma (5-20%), renal cancer (5-10%), and cancers of the gastrointestinal tract 
(5%) 1. The prognosis of patients with BM is usually poor, with a general median 
survival of several weeks in untreated patients and up to several months following 
oncological treatment. Some molecularly defined patient subsets, such as HER2-
positive breast cancer or ALK-positive non-small cell lung cancer, may demonstrate 
significantly longer survival.  Outcomes continue to improve with advances in systemic 
and regional therapy.   
 
Regional treatment options for BM are neurosurgical resection, radiotherapy (e.g., 
radiosurgery, fractionated external beam radiotherapy) and combinations thereof 2. 
Systemic treatment options such as targeted therapy and immunotherapy that can 
control both intracranial and extracranial disease are improving 3. Depending on the 
number of BM and the performance status of the patient, radiotherapy is an effective  
treatment of BM, either as whole-brain radiation therapy (WBRT) or, increasingly, as 
stereotactic radiosurgery (SRS) 4. Furthermore, surgery is frequently combined with 
post-operative radiotherapy, particularly in patients with single BM or oligometastatic 
brain disease 5. Despite various treatment options, BM recurrence is common.  
 
Contrast-enhanced magnetic resonance imaging (MRI) is the cornerstone of 
metastatic brain tumor evaluation. This technique has widespread availability and 
excellent spatial resolution, but can exhibit low specificity, resulting in substantial 
diagnostic challenges 6-8. These challenges include discriminating BM from potential 
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mimics that also demonstrate nodular or ring-enhancement.  Furthermore, MRI signal 
abnormalities including T2 or FLAIR hyperintensity, newly diagnosed contrast-
enhancing lesions, or an increase in the extent of contrast enhancement are non-
specific findings that can be caused by a variety of entities including infection, 
inflammation, ischemia, demyelination, and treatment-related effects.  In particular, 
reactive changes after surgery, radiotherapy and systemic drug treatment can be 
difficult to distinguish from true disease relapse. This phenomenon of worsening 
treatment-related changes mimicking progression, termed pseudoprogression, is of 
clinical importance as potentially effective treatment might be erroneously terminated 
prematurely 9,10. Pseudoprogression is a concern not only following radiation-based 
therapies, but also following immunotherapy, where a not well-characterized subset of 
patients manifests delayed response to therapy or therapy-induced inflammation that 
can simulate progressive disease 11,12.  
 
Successful management of patients with BM relies on accurate and early assessment 
of treatment response. The ability to predict or quickly detect lack of response to 
treatment may enable the early discontinuance of a particular therapy, thereby 
preventing additional toxicity, and allowing for the earlier initiation of alternative 
therapy. Despite promising efforts in defining response criteria for BM 10,13, limitations 
remain, particularly with newer systemic treatment options such as targeted therapy 
and immunotherapy.  Modalities which provide additional information on tumor 
physiology, including metabolism and proliferation, are increasingly applied problem-
solving tools in patients with BM. 
 
One promising method to investigate tumor physiology is Positron Emission 
Tomography (PET).  PET uses a variety of radioactive tracers that target various 
N-O-D-18-00655R3 
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metabolic and molecular processes.  PET imaging can provide relevant additional 
information that enables improved disease assessment, especially in clinically 
equivocal situations. Notwithstanding other PET tracers, the use of PET with 
radiolabeled amino acids, in particular, has been validated as an important diagnostic 
tool in brain cancer 6,14-16.  The overexpression of LAT transports in BM make 
intracranial metastases a compelling target for amino acid PET imaging 17. 
 
In this review, the RANO working group provides evidence-based recommendations 
for the use of PET imaging using tracers of amino acid transport and other targets, 



















SEARCH STRATEGY, SELECTION CRITERIA AND LEVELS OF VALIDATION  
A PubMed search of the published literature with the combination of the search terms 
“brain metastasis / metastases”, “PET”, “positron”, “FDG”, “amino acid”, “methionine”, 
“FET”, “FDOPA”, “FLT”, “TSPO”, “PSMA”, “radiotherapy”, “radiation-induced changes 
/ radiation injury”, “radionecrosis”, “pseudoprogression”, “treatment monitoring”, 
“assessment of treatment response”, and “immunotherapy” prior to and inclusive of 
August 2018 was performed. Additionally, articles identified through searches of the 
authors’ own files were included in the search. Results of the search were evaluated 
by the working group with respect to the level of evidence and the grade of validation 
of the PET studies examined. As described previously 14,15, any study that correlated 
PET findings with histopathology was considered to represent the highest degree of 
validation. Next, correlation with MRI and with the patient’s clinical course was 
considered the second level of validation. Only papers constituting levels 1-3 evidence 
according to the Oxford Centre for Evidence-based Medicine (The Oxford 2011 Levels 
of Evidence) were included. In brief, a randomized controlled trial fulfills the criteria for 
Oxford level 1, a prospective cohort study corresponds to level 2, and a retrospective 












PET TRACERS FOR IMAGING OF PATIENTS WITH BRAIN METASTASES 
In the following paragraphs, available PET tracers which address various 
pathophysiological pathways or molecular entities in BM are summarized.  
  
Glucose PET  
18F-2-fluoro-2-deoxy-D-glucose (FDG) represents the most widely used tracer in 
oncologic PET imaging and has evolved over the last several decades into the 
paramount clinical PET modality for cancer detection 18. Due to the long half-life of the 
fluorine-18 isotope (110 minutes), in-house production of this tracer is not necessary, 
overcoming logistic problems that occur with isotopes of shorter half-life. Thus, FDG 
can be transported to all PET centers, alleviating the need for an on-site cyclotron-
based manufacturing. Increased FDG uptake is commonly seen in highly proliferating 
cancer cells because of increased expression of glucose transporters and hexokinase, 
the enzyme that converts glucose (and FDG) to a phosphorylated product. Related to 
increased glycolysis, the uptake of FDG in neoplastic tissue is generally higher than in 
non-neoplastic tissue. However, the high and regionally variable FDG uptake in normal 
brain parenchyma often makes the delineation of tumors in the brain difficult 14 (Fig. 
1). Furthermore, inflammatory tissue can exhibit high FDG tracer uptake, also 
diminishing diagnostic specificity 6. 
 
Amino Acid PET Tracers  
For decades, radiolabeled amino acids are being used in neurooncological practice 19. 
11C-methyl-L-methionine (MET), an essential amino acid labeled with the isotope 
carbon-11, has been the most commonly employed 18,20.  The relatively short half-life 
of carbon-11 (20 minutes) limits its use to PET facilities with an on-site cyclotron. 
Consequently, other amino acids labeled with the positron-emitting isotope 18F, which 
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has a half-life of 110 minutes, have been developed, resulting in improved distribution, 
efficiency and cost-effectiveness 21. For example, O-(2-[18F]fluoroethyl)-L-tyrosine 
(FET) was developed in the late 1990s and its used has grown rapidly, particularly in 
Western Europe, in recent years. 22-24  Clinical results in glioma patients with PET using 
FET appear to be comparable to MET 25-27. In 2014, FET was approved as a medical 
drug in Europe (Switzerland) 28.  
 
3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA) is another 18F-labelled amino 
acid analogue, which was initially developed to evaluate dopamine synthesis in the 
basal ganglia and has also increasingly been used for imaging brain tumors 29. In the 
United States and Western Europe FDOPA is approved for characterization of 
presynaptic dopaminergic activity in patients with Parkinsonian syndromes.   
 
In both gliomas and BM, increased uptake of MET, FET and FDOPA is due to large 
neutral amino acid transporters of the L type (LAT), which are overexpressed in 
neoplastic tissue (subtypes LAT1 and LAT2) 17,30-32.  Overexpression of LAT1, and 
therefore robustness of amino acid tracer uptake, closely correlates with malignant 
phenotype and proliferation of gliomas 33. Compared to MET and FDOPA, FET has 
high metabolic stability. After transport by LAT transporters into neoplastic tissue, FET 
is not metabolized 25 whereas both MET and FDOPA show incorporation into protein, 
participation in other metabolic pathways or metabolic degradation 34.  
 
Acquisition of dynamic FET PET data allows characterization of the temporal pattern 
of FET uptake by deriving a time-activity curve (TAC). It has been demonstrated that 
TAC parameters (e.g., configuration, time-to-peak, slope) contain additional diagnostic 
information, which may be particularly valuable in the differentiation of BM recurrence 
N-O-D-18-00655R3 
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from radiation-induced changes 35-37. Similarly, the ability of dynamic FET PET to 
distinguish recurrent glioma from radiation-induced treatment effect has also been 
described 38,39.  Dynamic FET PET imaging is also helpful for glioma grading 40,41 and 
for determining the prognosis of untreated gliomas 42,43.  Such utility has yet to be 
observed for dynamic MET or FDOPA PET 44,45. 
 
Lastly, the amino acid PET tracer α-11C-methyl-L-tryptophan (AMT) has recently been 
employed for brain tumor imaging in some centers 46. However, despite promising 
results in terms of differential diagnosis in patients with newly diagnosed brain tumors 
including BM, the current literature is relatively small 47. 
 
Other PET Tracers  
Only few studies that have used non-FDG and non-amino acid PET tracer imaging in 
patients with BM. Tracers such as 18F-sodium fluoride (18F-NaF), 3´-deoxy-3´-18F-
fluorothymidine (18F-FLT), 82Rubidium as well as PET tracers targeting the endothelial 
prostate-specific membrane antigen (PSMA) have mostly been used for BM 
visualization and the assessment of treatment response 48-54. Choline derivates (e.g., 
18F-choline), which are in use for the diagnosis of recurrent prostate cancer, have also 
been reported to label BM 55,56. Animal studies have found that PET imaging using 
agents targeting the mitochondrial translocator protein (TSPO), which is upregulated 
on activated microglia, may be helpful for BM detection at an early stage of 
development 57. Despite promising results, experience with these tracers are mainly 
based on single cases in patients with BM and their usefulness needs to be confirmed 





CLINICAL APPLICATIONS FOR PET IMAGING IN PATIENTS WITH BRAIN 
METASTASIS 
 
Identification of Newly Diagnosed and Untreated Brain Metastasis Using FDG 
and Amino Acid PET  
Although conventional MRI is the method of choice for the detection of BM, some 
centers include the head for whole-body FDG PET/CT staging examinations of cancer 
patients. However, the value of this procedure is highly questionable based on the 
limited sensitivity of FDG PET for brain tumors related to the physiologically high levels 
of glucose metabolism in healthy brain parenchyma 58,59. Indeed, a prospective study 
has shown that, in comparison to contrast-enhanced standard MRI for intracranial 
staging in newly diagnosed lung cancer, FDG PET has poor sensitivity (27%) for BM 
detection 60. Similarly, a recent meta-analysis including more than 900 patients found 
that contrast-enhanced MRI has a higher cumulative sensitivity (77%) than FDG PET 
(21%) for the diagnosis of BM in lung cancer patients 61. 
 
The increased expression of amino acid transporters in BM compared to healthy brain 
tissue renders radiolabeled amino acids suitable for PET imaging based on high tumor-
to-background contrast 17. Compared to FDG PET, the sensitivity of amino acid PET 
using FET to depict larger (> 1 cm in diameter) BM seems to be clearly higher 
(approximately 90% of BM were FET positive based on a maximum tumor/brain ratio 
≥ 1.6) 62. However, detection of lesions with < 1 cm diameter may be considerably 
inferior to that of MRI. For example, in a pilot study of patients with newly diagnosed 
and untreated BM which correlated FET uptake characteristics with MRI parameters, 
the sensitivity of standard MRI for the detection of BM was 100% 62. Currently, the 
N-O-D-18-00655R3 
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most sensitive and commonly used imaging modality for the detection of BM remains 
thin-slice contrast-enhanced MRI. 
 
 Amino acid PET using the tracer FET has higher diagnostic accuracy for the 
detection of BM than FDG PET (evidence level 2). 
 
 FDG or amino acid PET are limited in detecting smaller metastases, particularly 
those less than 1 cm in diameter. 
 




Differential Diagnosis of Newly Diagnosed and Untreated Brain Metastasis Using 
FDG and Amino Acid PET  
FDG PET is limited in its ability to differentiate BM from mimics such as glioblastoma:  
it has been shown that there is no significant difference in FDG standardized uptake 
values (SUV) between these entities 63,64.  Differentiation between CNS lymphoma and 
BM based on FDG PET is more promising, as lymphoma may be substantially more 
FDG avid than BM 63,64.  Initial data suggest that SUVs of the radiolabeled amino acid 
AMT are lower in BM than in glioblastomas 47.  Further studies are required to firmly 
establish the added value of PET ligands to differentiate various lesions that have 
similar MRI characteristics.  
 
High levels of LAT expression in cancer cells has been reported to correlate with 
aggressive tumor features and a worse prognosis 65,66. LAT expression also appears 
N-O-D-18-00655R3 
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to be higher in recurrent compared to newly diagnosed BM 17. However, there are no 
studies yet investigating the prognostic value of amino acid PET in patients with BM. 
Possible limitations include the observation that uptake intensity as well as LAT 
expression levels are highly variable, even in metastases of the same primary tumor 
type 65,66. Thus, the site of origin of BM cannot be based on amino acid PET findings 
62. 
 
In contrast to glioma, the size and volume of a BM are usually well delineated on 
contrast-enhanced MRI. Thus, amino acid PET does not add valuable information for 
biopsy or treatment planning as has been found for newly diagnosed gliomas 67,68.  
 
 There is limited evidence to support the use of PET to distinguish between BM 
and high-grade glioma (evidence level 3).  
 
 Evidence is lacking for the use of amino acid PET to determine prognosis in 
patients with BM. 
 
 
Differentiation of Radiation-induced Changes from Brain Metastasis Recurrence 
Using FDG and Amino Acid PET  
Oncologists of all subspecialties are often confronted with the clinical problem of 
differentiating tumor recurrence from treatment-related changes following radiation 
therapy, and in particular after high-dose focal radiation (i.e., radiosurgery or 
fractionated stereotactic radiation therapy). Currently, conventional MRI does not 
reliably differentiate local brain tumor recurrence or progression from radiation-induced 
changes including radiation necrosis. In gliomas, radiation necrosis usually manifests 
N-O-D-18-00655R3 
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within 6-12 months after standard fractionated radiotherapy and occurs in 
approximately 5-25% of all treated patients 69,70. For patients with BM treated by 
radiosurgery, a similar rate of radiation necrosis (approximately 25%) has been 
reported 71, although the incidence depends on the radiation dose and irradiated brain 
volume.  Indeed, in some cases the risk of radiation necrosis may be as high as 50% 
71. It should be noted that this wide variation in reported incidence is also likely a 
consequence of varying definitions of treatment-related changes in retrospective 
studies, including clinical data such as whether the patient is symptomatic or not. 
Treatment-related changes represent a spectrum of pathophysiology that may be 
purely radiographic and lack associated symptoms, but also may be symptomatic, 
refractory to corticosteroids, and require neurosurgical or other intervention. 
 
FDG PET 
In recent years, FDG PET has been studied as an additional neuroimaging tool to 
differentiate treatment-related effects from true BM progression (Table 1). 
Unfortunately, these investigations included few patients and were limited by variations 
in methodology such as thresholds used for the differentiation of radiation-induced 
changes from BM recurrence. Perhaps as a result, the diagnostic performance of FDG 
PET varied considerably (range of sensitivity, 40-95%; range of specificity, 50-100%) 
(Table 1). Dual phase FDG PET may be superior to standard (single phase) scans 72, 
but limited by long time intervals between scans (median time between FDG PET 
scans, 3.8 hours; range, 2-5.7 hours), 72 hampering routine clinical use. The diagnostic 
performance of FDG PET also seems to be inferior to several other imaging methods 
such as MET PET 73, MRI-based perfusion imaging with arterial spin labeling (ASL) 74, 




Amino acid PET 
Amino acid PET has also been investigated as an imaging modality to distinguish 
treatment effect from tumor in clinical practice (Table 2). It has been demonstrated that 
MET PET may differentiate recurrent BM from radiation-induced changes using an 
easily applicable semi-quantitative regions-of-interest (ROI) analysis for the calculation 
of tumor/brain ratios. MET PET has demonstrated a sensitivity and specificity of 70-
80% in differentiating treatment effect from recurrent tumor 77-79. It has also been 
shown that FDOPA PET is able to differentiate recurrent BM from radiation-induced 
changes with high sensitivity and specificity (81% and 84%, respectively) 80 (Fig. 1). 
Another study has reported an accuracy of 91% for differentiating radiation-induced 
changes from BM progression after radiosurgery for FDOPA PET, out-performing 
perfusion MRI parameters 91% to 76% 81.  A similar high diagnostic performance has 
also been demonstrated for FET PET; using tumor/brain ratios and dynamic 
parameters, FET PET differentiated radiation-induced changes from locally recurrent 
BM with a sensitivity of 95% and specificity of 91% 35 (Fig. 2). Dynamic FET PET 
studies in a larger number of patients demonstrated a sensitivity and specificity of 80-
90% 36,37. Furthermore, the diagnostic performance of amino acid PET seems to be 
superior to both FDG PET and MRI-based perfusion- and diffusion-weighted imaging, 
73,81 (Table 2). Across all available amino acid PET studies for this indication, 
histological confirmation of diagnosis (i.e., BM recurrence or radiation injury) ranges 
from 11-56% (Table 2). The cost effectiveness of amino acid PET has been 
demonstrated in Europe for the differentiation of recurrent BM and radiation-induced 
changes 82 and various other indications 83-85. 
 
Recent literature highlights the value of PET radiomics in assessing tumor phenotypes 
86. Radiomics enables the high-throughput extraction of a large number of quantitative 
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features from imaging of a standard modality (usually MRI and PET) 87,88. One 
application of radiomics is the use of textural feature analysis which objectively and 
quantitatively describes intrinsic properties of tumors, particularly heterogeneity. Using 
FET PET, it has been demonstrated that radiomic textural feature analysis provide 
non-invasive quantitative information useful for distinguishing treatment-related 
changes from disease progression 89. Combined FET PET and MRI radiomics using 
textural features achieved a diagnostic specificity of more than 90% 90. 
 
 Amino acid PET is useful in distinguishing post-therapeutic reactive changes 
following radiotherapy from recurrent BM. Present studies consistently show 
high diagnostic accuracy (evidence level 2). 
 
 FDG PET can also be used for this indication, but studies to date report highly 
variable diagnostic accuracy (evidence level 2). 
 
 At present, direct comparisons of advanced MRI versus PET are limited. Amino 
acid PET may be more useful than advanced MRI, whereas FDG PET appears 
to be inferior (evidence level 3). 
 
 When using PET for this indication, amino acid tracers should be the preferred. 
Dynamic FET PET may further improve diagnostic accuracy. 
 
 
Differentiation of Treatment-related Changes of Immunotherapy from Brain 
Metastasis Recurrence using FDG and Amino Acid PET 
Immuno-oncology is a rapidly developing therapeutic field with potential applications 
in CNS malignancies, particularly in patients with BM 91. Early phase studies have 
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illustrated diagnostic challenges associated with the assessment of radiological 
changes in response to immunotherapy, wherein a subset of patients manifests 
delayed response to therapy or therapy-induced inflammation that mimic progressive 
disease. Following immunotherapy, long-term survival and tumor regression may 
occur after what was believed to represent initial disease progression or even after the 
appearance of new lesions 11. Pseudoprogression may occur in patients with BM 
treated with immunotherapy using checkpoint inhibitors such as CTLA-4 (cytotoxic T 
lymphocyte-associated antigen 4; e.g., ipilimumab) and PD-1 (programmed cell death 
1 receptor; e.g., pembrolizumab or nivolumab) inhibitors 11,12,92,93. A pilot study showed 
the potential of FET PET to identify pseudoprogression in patients with BM originating 
from melanoma treated with immune checkpoint inhibitors 94. Data on FDG PET for 
this indication are currently not available. 
 
 At present, there is limited evidence of the potential benefit of amino acid PET 
for differentiating pseudoprogression from true disease progression following 
checkpoint inhibitor blockade (evidence level 3). 
 
 
Assessment of Treatment Response  
As stated above, standard MRI is limited in its ability to differentiate BM relapse from 
treatment-related effects such as radionecrosis or pseudoprogression, all of which can 
induce contrast enhancement and T2/FLAIR hyperintensity. The use of FDG as a 
tracer for the assessment of treatment response in PET imaging is hampered by high 
physiologic brain uptake, limiting the discrimination between tumor and normal brain 
metabolic activity 14. Furthermore, in light of newer systemic treatment options such as 
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targeted therapy and immunotherapy, tools which provide additional information on 
cellular physiology (e.g., metabolism, proliferation) have become increasingly useful. 
 
The PET tracer FLT is an analog to the nucleoside thymidine and was developed as a 
PET agent to assess cellular proliferation by tracking the thymidine salvage pathway 
95.  Recently, FLT has been applied to assess response to the chemotherapeutic agent 
ANG1005 (a drug conjugate consisting of paclitaxel covalently linked to Angiopep-2, 
designed to cross the blood-brain barrier) in patients with BM originating from breast 
cancer and was found to supplement the information derived from contrast-enhanced 
MRI by clarifying equivocal MRI findings 50. 
 
In BM from malignant melanoma being treated with targeted therapy and 
immunotherapy, a small study found in a subset of patients that metabolic responders 
may show a proliferative reduction on FLT PET despite apparent morphologic 
progression on standard MRI (i.e., pseudoprogression) 54. 
 
Studies evaluating amino acid PET for the assessment of treatment response are 
lacking. Theoretically, amino acid PET has the potential to add valuable information to 
standard MRI for the assessment of treatment response; validation in clinical studies 
is required. An illustrative example for this potential indication is presented in Figure 3. 
 
 Currently only preliminary evidence exists for a potential benefit of PET for the 








CURRENT LIMITATIONS AND FUTURE PERSPECTIVE  
 
At present, the differentiation of radiation injury from BM recurrence using amino acid 
PET has been the most thoroughly investigated indication (Table 3), repeatedly 
demonstrating high diagnostic accuracy. However, it should be noted that these data 
were derived mainly from retrospective analyses performed in single centers, and 
diagnoses were not consistently confirmed histologically. Prospective multicenter 
studies are therefore needed to validate initial results of these proof-of-principle 
investigations. Challenges of prospective validation are several, including 
heterogeneity of patient population, i.e., various originating cancers, number of BMs, 
and varying treatment regimens. Amino acid PET tracer availability and cost present 
additional obstacles. 
 
Contrary to gliomas and transosseous meningiomas, the majority of BM can be easily 
delineated by conventional MRI. Thus, PET imaging does not add significant additional 
information. Detecting multiple, small BM remains a major clinical challenge, potentially 
impacting not only prognosis, but also treatment (i.e., a shift from local treatment such 
as surgery or SRS to WBRT or systemic treatment options). Due to the limited spatial 
resolution of PET, miliary disseminated metastatic disease or leptomeningeal 
metastasis is challenging to assess and may be unapparent by current PET imaging. 
The still frequent use of FDG PET in the brain is of limited value due to poor lesion-to-
background contrast, partially explaining disappointing results in screened cohorts 96. 
New PET tracers, e.g., TSPO, might help to overcome this problem 97 and may 




PET imaging in meningiomas using specific somatostatin receptor ligands such as 
68Ga-DOTATATE PET has shown that tracer uptake may correlate with tumor grade 
as well as the likelihood of response to specific radionucleotide therapy 98,99. Intra-
individual variation in patients with multiple lesions has been noted 100. By analogy, 
further investigations should aim to non-invasively image intra-individual heterogeneity 
in patients with multiple BM. Optimal patient management may benefit by improved 
and well-validated prognostic and predictive imaging markers derived from PET, as by 
the identification and quantification of target molecules for specific therapy, e.g., EGFR 
101-103. Moreover, this could lead to early response markers of successful treatment 
that can be determined prior to changes in tumor size. Lastly, more specific PET 
tracers could potentially better identify BM primary cancer of origin.  
 
By altering radioisotopes, PET ligands initially used for diagnostic imaging might also 
be instrumental for therapy. This concept of “theranostics” has already been introduced 
into the management of prostate cancer 104-106. Moreover, PET might help in the future 
to identify drug delivery into tumor tissue and provide imaging-based data on inter- and 
intra-individual variability of tumor drug concentration, thereby permitting more relevant 
information for patient selection and therapy tailoring 107,108. 
 
Another methodological innovation which could advance research in patients with BM 
is the increasing availability of hybrid PET/MR scanners, allowing the simultaneous 
acquisition of both imaging modalities. For example, the acquisition of dynamic FET 
PET, contrast-enhanced structural and perfusion-weighted MRI, and other advanced 
MRI sequences such as MR spectroscopy and functional MRI in a single session 
(“one-stop shop”) can now be performed. Besides optimizing co-registration of various 
imaging modalities, this technology appears particularly attractive for BM patients with 
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poor clinical condition by considerably reducing scanning time and avoiding exposure 
to additional radiation dose associated with a PET/CT scan. From a research 
perspective, hybrid PET/MR technology provides a convenient platform for 
comparative imaging studies using amino acid PET and advanced MR imaging, ideally 
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Figure 1: 56-year old female patient with a brain metastasis originating from a papillary 
thyroid carcinoma treated with radiosurgery. Follow-up MR imaging 15 months later 
(top row, left) is consistent with stable disease according to RANO criteria for brain 
metastases. Most probably due to the lesion size, the corresponding FDG PET (top 
row, right) shows no increased metabolic activity. During the next 12 months, the size 
of contrast enhancement increased marginally (bottom row, left). Notwithstanding the 
small lesion size on anatomical MRI, the corresponding FDOPA PET (bottom row, 
right) shows clearly increased metabolic activity indicating brain metastasis relapse. 
 
Figure 2: 50-year old female patient with a brain metastasis secondary to non-small 
cell lung cancer underwent hybrid PET/MR imaging. Six months after stereotactic 
radiosurgery, MRI suggests tumor recurrence. In contrast, FET PET shows no 
increased metabolic activity (TBRmean = 1.3), and the time-activity curve shows a 
steadily increasing FET uptake, indicating radiation injury. The diagnosis was 
confirmed by subsequent hybrid PET/MR imaging 3 months later demonstrating 
improvement of imaging findings without a therapeutic intervention. 
 
Figure 3: 45-year old female patient with a brain metastasis secondary to a BRAF-
mutated malignant melanoma treated with dabrafenib and trametinib. Comparison of 
contrast-enhanced MR and FET PET images at baseline (left column) and follow-up 
eight weeks later (right column). At follow-up, a clear decrease of the tumor/brain ratios 
(-35%) is observed whereas the MRI shows no significant change of both the contrast 
enhancement and FLAIR signal defined as stable disease according to RANO criteria 
for brain metastases. The metabolic response was associated with an overall survival 
of 9 months after treatment initiation. 
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Brain metastases (BM) from extracranial cancer are associated with significant 
morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, 
including radiosurgery or fractionated external beam radiotherapy, and surgical 
resection. The use of systemic treatment for intracranial disease control also is 
improving.  BM diagnosis, treatment planning and follow-up is most often based on 
contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging 
modalities including standard MRI have limitations in accurately characterizing post-
therapeutic reactive changes and treatment response. Molecular imaging techniques 
such as positron emission tomography (PET) characterize specific metabolic and 
cellular features of metastases, potentially providing clinically relevant information 
supplementing anatomic MRI. Here, the RANO working group provides 
recommendations for the use of PET imaging in the clinical management of patients 
with BM based on evidence from studies validated by histology and/or clinical outcome. 
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Brain metastases (BM) often occur in advanced malignancies but may also be an initial 
disease manifestation in, for example, cancer of unknown primary (CUP). BM derive 
most frequently from lung cancer (40-50% of all BM), breast cancer (15-20%), 
melanoma (5-20%), renal cancer (5-10%), and cancers of the gastrointestinal tract 
(5%) 1. The prognosis of patients with BM is usually poor, with a general median 
survival of several weeks in untreated patients and up to several months following 
oncological treatment. Some molecularly defined patient subsets, such as HER2-
positive breast cancer or ALK-positive non-small cell lung cancer, may demonstrate 
significantly longer survival.  Outcomes continue to improve with advances in systemic 
and regional therapy.   
 
Regional treatment options for BM are neurosurgical resection, radiotherapy (e.g., 
radiosurgery, fractionated external beam radiotherapy) and combinations thereof 2. 
Systemic treatment options such as targeted therapy and immunotherapy that can 
control both intracranial and extracranial disease are improving 3. Depending on the 
number of BM and the performance status of the patient, radiotherapy is an effective  
treatment of BM, either as whole-brain radiation therapy (WBRT) or, increasingly, as 
stereotactic radiosurgery (SRS) 4. Furthermore, surgery is frequently combined with 
post-operative radiotherapy, particularly in patients with single BM or oligometastatic 
brain disease 5. Despite various treatment options, BM recurrence is common.  
 
Contrast-enhanced magnetic resonance imaging (MRI) is the cornerstone of 
metastatic brain tumor evaluation. This technique has widespread availability and 
excellent spatial resolution, but can exhibit low specificity, resulting in substantial 
diagnostic challenges 6-8. These challenges include discriminating BM from potential 
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mimics that also demonstrate nodular or ring-enhancement.  Furthermore, MRI signal 
abnormalities including T2 or FLAIR hyperintensity, newly diagnosed contrast-
enhancing lesions, or an increase in the extent of contrast enhancement are non-
specific findings that can be caused by a variety of entities including infection, 
inflammation, ischemia, demyelination, and treatment-related effects.  In particular, 
reactive changes after surgery, radiotherapy and systemic drug treatment can be 
difficult to distinguish from true disease relapse. This phenomenon of worsening 
treatment-related changes mimicking progression, termed pseudoprogression, is of 
clinical importance as potentially effective treatment might be erroneously terminated 
prematurely 9,10. Pseudoprogression is a concern not only following radiation-based 
therapies, but also following immunotherapy, where a not well-characterized subset of 
patients manifests delayed response to therapy or therapy-induced inflammation that 
can simulate progressive disease 11,12.  
 
Successful management of patients with BM relies on accurate and early assessment 
of treatment response. The ability to predict or quickly detect lack of response to 
treatment may enable the early discontinuance of a particular therapy, thereby 
preventing additional toxicity, and allowing for the earlier initiation of alternative 
therapy. Despite promising efforts in defining response criteria for BM 10,13, limitations 
remain, particularly with newer systemic treatment options such as targeted therapy 
and immunotherapy.  Modalities which provide additional information on tumor 
physiology, including metabolism and proliferation, are increasingly applied problem-
solving tools in patients with BM. 
 
One promising method to investigate tumor physiology is Positron Emission 
Tomography (PET).  PET uses a variety of radioactive tracers that target various 
N-O-D-18-00655R3 
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metabolic and molecular processes.  PET imaging can provide relevant additional 
information that enables improved disease assessment, especially in clinically 
equivocal situations. Notwithstanding other PET tracers, the use of PET with 
radiolabeled amino acids, in particular, has been validated as an important diagnostic 
tool in brain cancer 6,14-16.  The overexpression of LAT transports in BM make 
intracranial metastases a compelling target for amino acid PET imaging 17. 
 
In this review, the RANO working group provides evidence-based recommendations 
for the use of PET imaging using tracers of amino acid transport and other targets, 



















SEARCH STRATEGY, SELECTION CRITERIA AND LEVELS OF VALIDATION  
A PubMed search of the published literature with the combination of the search terms 
“brain metastasis / metastases”, “PET”, “positron”, “FDG”, “amino acid”, “methionine”, 
“FET”, “FDOPA”, “FLT”, “TSPO”, “PSMA”, “radiotherapy”, “radiation-induced changes 
/ radiation injury”, “radionecrosis”, “pseudoprogression”, “treatment monitoring”, 
“assessment of treatment response”, and “immunotherapy” prior to and inclusive of 
August 2018 was performed. Additionally, articles identified through searches of the 
authors’ own files were included in the search. Results of the search were evaluated 
by the working group with respect to the level of evidence and the grade of validation 
of the PET studies examined. As described previously 14,15, any study that correlated 
PET findings with histopathology was considered to represent the highest degree of 
validation. Next, correlation with MRI and with the patient’s clinical course was 
considered the second level of validation. Only papers constituting levels 1-3 evidence 
according to the Oxford Centre for Evidence-based Medicine (The Oxford 2011 Levels 
of Evidence) were included. In brief, a randomized controlled trial fulfills the criteria for 
Oxford level 1, a prospective cohort study corresponds to level 2, and a retrospective 












PET TRACERS FOR IMAGING OF PATIENTS WITH BRAIN METASTASES 
In the following paragraphs, available PET tracers which address various 
pathophysiological pathways or molecular entities in BM are summarized.  
  
Glucose PET  
18F-2-fluoro-2-deoxy-D-glucose (FDG) represents the most widely used tracer in 
oncologic PET imaging and has evolved over the last several decades into the 
paramount clinical PET modality for cancer detection 18. Due to the long half-life of the 
fluorine-18 isotope (110 minutes), in-house production of this tracer is not necessary, 
overcoming logistic problems that occur with isotopes of shorter half-life. Thus, FDG 
can be transported to all PET centers, alleviating the need for an on-site cyclotron-
based manufacturing. Increased FDG uptake is commonly seen in highly proliferating 
cancer cells because of increased expression of glucose transporters and hexokinase, 
the enzyme that converts glucose (and FDG) to a phosphorylated product. Related to 
increased glycolysis, the uptake of FDG in neoplastic tissue is generally higher than in 
non-neoplastic tissue. However, the high and regionally variable FDG uptake in normal 
brain parenchyma often makes the delineation of tumors in the brain difficult 14 (Fig. 
1). Furthermore, inflammatory tissue can exhibit high FDG tracer uptake, also 
diminishing diagnostic specificity 6. 
 
Amino Acid PET Tracers  
For decades, radiolabeled amino acids are being used in neurooncological practice 19. 
11C-methyl-L-methionine (MET), an essential amino acid labeled with the isotope 
carbon-11, has been the most commonly employed 18,20.  The relatively short half-life 
of carbon-11 (20 minutes) limits its use to PET facilities with an on-site cyclotron. 
Consequently, other amino acids labeled with the positron-emitting isotope 18F, which 
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has a half-life of 110 minutes, have been developed, resulting in improved distribution, 
efficiency and cost-effectiveness 21. For example, O-(2-[18F]fluoroethyl)-L-tyrosine 
(FET) was developed in the late 1990s and its used has grown rapidly, particularly in 
Western Europe, in recent years. 22-24  Clinical results in glioma patients with PET using 
FET appear to be comparable to MET 25-27. In 2014, FET was approved as a medical 
drug in Europe (Switzerland) 28.  
 
3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA) is another 18F-labelled amino 
acid analogue, which was initially developed to evaluate dopamine synthesis in the 
basal ganglia and has also increasingly been used for imaging brain tumors 29. In the 
United States and Western Europe FDOPA is approved for characterization of 
presynaptic dopaminergic activity in patients with Parkinsonian syndromes.   
 
In both gliomas and BM, increased uptake of MET, FET and FDOPA is due to large 
neutral amino acid transporters of the L type (LAT), which are overexpressed in 
neoplastic tissue (subtypes LAT1 and LAT2) 17,30-32.  Overexpression of LAT1, and 
therefore robustness of amino acid tracer uptake, closely correlates with malignant 
phenotype and proliferation of gliomas 33. Compared to MET and FDOPA, FET has 
high metabolic stability. After transport by LAT transporters into neoplastic tissue, FET 
is not metabolized 25 whereas both MET and FDOPA show incorporation into protein, 
participation in other metabolic pathways or metabolic degradation 34.  
 
Acquisition of dynamic FET PET data allows characterization of the temporal pattern 
of FET uptake by deriving a time-activity curve (TAC). It has been demonstrated that 
TAC parameters (e.g., configuration, time-to-peak, slope) contain additional diagnostic 
information, which may be particularly valuable in the differentiation of BM recurrence 
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from radiation-induced changes 35-37. Similarly, the ability of dynamic FET PET to 
distinguish recurrent glioma from radiation-induced treatment effect has also been 
described 38,39.  Dynamic FET PET imaging is also helpful for glioma grading 40,41 and 
for determining the prognosis of untreated gliomas 42,43.  Such utility has yet to be 
observed for dynamic MET or FDOPA PET 44,45. 
 
Lastly, the amino acid PET tracer α-11C-methyl-L-tryptophan (AMT) has recently been 
employed for brain tumor imaging in some centers 46. However, despite promising 
results in terms of differential diagnosis in patients with newly diagnosed brain tumors 
including BM, the current literature is relatively small 47. 
 
Other PET Tracers  
Only few studies that have used non-FDG and non-amino acid PET tracer imaging in 
patients with BM. Tracers such as 18F-sodium fluoride (18F-NaF), 3´-deoxy-3´-18F-
fluorothymidine (18F-FLT), 82Rubidium as well as PET tracers targeting the endothelial 
prostate-specific membrane antigen (PSMA) have mostly been used for BM 
visualization and the assessment of treatment response 48-54. Choline derivates (e.g., 
18F-choline), which are in use for the diagnosis of recurrent prostate cancer, have also 
been reported to label BM 55,56. Animal studies have found that PET imaging using 
agents targeting the mitochondrial translocator protein (TSPO), which is upregulated 
on activated microglia, may be helpful for BM detection at an early stage of 
development 57. Despite promising results, experience with these tracers are mainly 
based on single cases in patients with BM and their usefulness needs to be confirmed 





CLINICAL APPLICATIONS FOR PET IMAGING IN PATIENTS WITH BRAIN 
METASTASIS 
 
Identification of Newly Diagnosed and Untreated Brain Metastasis Using FDG 
and Amino Acid PET  
Although conventional MRI is the method of choice for the detection of BM, some 
centers include the head for whole-body FDG PET/CT staging examinations of cancer 
patients. However, the value of this procedure is highly questionable based on the 
limited sensitivity of FDG PET for brain tumors related to the physiologically high levels 
of glucose metabolism in healthy brain parenchyma 58,59. Indeed, a prospective study 
has shown that, in comparison to contrast-enhanced standard MRI for intracranial 
staging in newly diagnosed lung cancer, FDG PET has poor sensitivity (27%) for BM 
detection 60. Similarly, a recent meta-analysis including more than 900 patients found 
that contrast-enhanced MRI has a higher cumulative sensitivity (77%) than FDG PET 
(21%) for the diagnosis of BM in lung cancer patients 61. 
 
The increased expression of amino acid transporters in BM compared to healthy brain 
tissue renders radiolabeled amino acids suitable for PET imaging based on high tumor-
to-background contrast 17. Compared to FDG PET, the sensitivity of amino acid PET 
using FET to depict larger (> 1 cm in diameter) BM seems to be clearly higher 
(approximately 90% of BM were FET positive based on a maximum tumor/brain ratio 
≥ 1.6) 62. However, detection of lesions with < 1 cm diameter may be considerably 
inferior to that of MRI. For example, in a pilot study of patients with newly diagnosed 
and untreated BM which correlated FET uptake characteristics with MRI parameters, 
the sensitivity of standard MRI for the detection of BM was 100% 62. Currently, the 
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most sensitive and commonly used imaging modality for the detection of BM remains 
thin-slice contrast-enhanced MRI. 
 
 Amino acid PET using the tracer FET has higher diagnostic accuracy for the 
detection of BM than FDG PET (evidence level 2). 
 
 FDG or amino acid PET are limited in detecting smaller metastases, particularly 
those less than 1 cm in diameter. 
 




Differential Diagnosis of Newly Diagnosed and Untreated Brain Metastasis Using 
FDG and Amino Acid PET  
FDG PET is limited in its ability to differentiate BM from mimics such as glioblastoma:  
it has been shown that there is no significant difference in FDG standardized uptake 
values (SUV) between these entities 63,64.  Differentiation between CNS lymphoma and 
BM based on FDG PET is more promising, as lymphoma may be substantially more 
FDG avid than BM 63,64.  Initial data suggest that SUVs of the radiolabeled amino acid 
AMT are lower in BM than in glioblastomas 47.  Further studies are required to firmly 
establish the added value of PET ligands to differentiate various lesions that have 
similar MRI characteristics.  
 
High levels of LAT expression in cancer cells has been reported to correlate with 
aggressive tumor features and a worse prognosis 65,66. LAT expression also appears 
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to be higher in recurrent compared to newly diagnosed BM 17. However, there are no 
studies yet investigating the prognostic value of amino acid PET in patients with BM. 
Possible limitations include the observation that uptake intensity as well as LAT 
expression levels are highly variable, even in metastases of the same primary tumor 
type 65,66. Thus, the site of origin of BM cannot be based on amino acid PET findings 
62. 
 
In contrast to glioma, the size and volume of a BM are usually well delineated on 
contrast-enhanced MRI. Thus, amino acid PET does not add valuable information for 
biopsy or treatment planning as has been found for newly diagnosed gliomas 67,68.  
 
 There is limited evidence to support the use of PET to distinguish between BM 
and high-grade glioma (evidence level 3).  
 
 Evidence is lacking for the use of amino acid PET to determine prognosis in 
patients with BM. 
 
 
Differentiation of Radiation-induced Changes from Brain Metastasis Recurrence 
Using FDG and Amino Acid PET  
Oncologists of all subspecialties are often confronted with the clinical problem of 
differentiating tumor recurrence from treatment-related changes following radiation 
therapy, and in particular after high-dose focal radiation (i.e., radiosurgery or 
fractionated stereotactic radiation therapy). Currently, conventional MRI does not 
reliably differentiate local brain tumor recurrence or progression from radiation-induced 
changes including radiation necrosis. In gliomas, radiation necrosis usually manifests 
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within 6-12 months after standard fractionated radiotherapy and occurs in 
approximately 5-25% of all treated patients 69,70. For patients with BM treated by 
radiosurgery, a similar rate of radiation necrosis (approximately 25%) has been 
reported 71, although the incidence depends on the radiation dose and irradiated brain 
volume.  Indeed, in some cases the risk of radiation necrosis may be as high as 50% 
71. It should be noted that this wide variation in reported incidence is also likely a 
consequence of varying definitions of treatment-related changes in retrospective 
studies, including clinical data such as whether the patient is symptomatic or not. 
Treatment-related changes represent a spectrum of pathophysiology that may be 
purely radiographic and lack associated symptoms, but also may be symptomatic, 
refractory to corticosteroids, and require neurosurgical or other intervention. 
 
FDG PET 
In recent years, FDG PET has been studied as an additional neuroimaging tool to 
differentiate treatment-related effects from true BM progression (Table 1). 
Unfortunately, these investigations included few patients and were limited by variations 
in methodology such as thresholds used for the differentiation of radiation-induced 
changes from BM recurrence. Perhaps as a result, the diagnostic performance of FDG 
PET varied considerably (range of sensitivity, 40-95%; range of specificity, 50-100%) 
(Table 1). Dual phase FDG PET may be superior to standard (single phase) scans 72, 
but limited by long time intervals between scans (median time between FDG PET 
scans, 3.8 hours; range, 2-5.7 hours), 72 hampering routine clinical use. The diagnostic 
performance of FDG PET also seems to be inferior to several other imaging methods 
such as MET PET 73, MRI-based perfusion imaging with arterial spin labeling (ASL) 74, 




Amino acid PET 
Amino acid PET has also been investigated as an imaging modality to distinguish 
treatment effect from tumor in clinical practice (Table 2). It has been demonstrated that 
MET PET may differentiate recurrent BM from radiation-induced changes using an 
easily applicable semi-quantitative regions-of-interest (ROI) analysis for the calculation 
of tumor/brain ratios. MET PET has demonstrated a sensitivity and specificity of 70-
80% in differentiating treatment effect from recurrent tumor 77-79. It has also been 
shown that FDOPA PET is able to differentiate recurrent BM from radiation-induced 
changes with high sensitivity and specificity (81% and 84%, respectively) 80 (Fig. 1). 
Another study has reported an accuracy of 91% for differentiating radiation-induced 
changes from BM progression after radiosurgery for FDOPA PET, out-performing 
perfusion MRI parameters 91% to 76% 81.  A similar high diagnostic performance has 
also been demonstrated for FET PET; using tumor/brain ratios and dynamic 
parameters, FET PET differentiated radiation-induced changes from locally recurrent 
BM with a sensitivity of 95% and specificity of 91% 35 (Fig. 2). Dynamic FET PET 
studies in a larger number of patients demonstrated a sensitivity and specificity of 80-
90% 36,37. Furthermore, the diagnostic performance of amino acid PET seems to be 
superior to both FDG PET and MRI-based perfusion- and diffusion-weighted imaging, 
73,81 (Table 2). Across all available amino acid PET studies for this indication, 
histological confirmation of diagnosis (i.e., BM recurrence or radiation injury) ranges 
from 11-56% (Table 2). The cost effectiveness of amino acid PET has been 
demonstrated in Europe for the differentiation of recurrent BM and radiation-induced 
changes 82 and various other indications 83-85. 
 
Recent literature highlights the value of PET radiomics in assessing tumor phenotypes 
86. Radiomics enables the high-throughput extraction of a large number of quantitative 
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features from imaging of a standard modality (usually MRI and PET) 87,88. One 
application of radiomics is the use of textural feature analysis which objectively and 
quantitatively describes intrinsic properties of tumors, particularly heterogeneity. Using 
FET PET, it has been demonstrated that radiomic textural feature analysis provide 
non-invasive quantitative information useful for distinguishing treatment-related 
changes from disease progression 89. Combined FET PET and MRI radiomics using 
textural features achieved a diagnostic specificity of more than 90% 90. 
 
 Amino acid PET is useful in distinguishing post-therapeutic reactive changes 
following radiotherapy from recurrent BM. Present studies consistently show 
high diagnostic accuracy (evidence level 2). 
 
 FDG PET can also be used for this indication, but studies to date report highly 
variable diagnostic accuracy (evidence level 2). 
 
 At present, direct comparisons of advanced MRI versus PET are limited. Amino 
acid PET may be more useful than advanced MRI, whereas FDG PET appears 
to be inferior (evidence level 3). 
 
 When using PET for this indication, amino acid tracers should be the preferred. 
Dynamic FET PET may further improve diagnostic accuracy. 
 
 
Differentiation of Treatment-related Changes of Immunotherapy from Brain 
Metastasis Recurrence using FDG and Amino Acid PET 
Immuno-oncology is a rapidly developing therapeutic field with potential applications 
in CNS malignancies, particularly in patients with BM 91. Early phase studies have 
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illustrated diagnostic challenges associated with the assessment of radiological 
changes in response to immunotherapy, wherein a subset of patients manifests 
delayed response to therapy or therapy-induced inflammation that mimic progressive 
disease. Following immunotherapy, long-term survival and tumor regression may 
occur after what was believed to represent initial disease progression or even after the 
appearance of new lesions 11. Pseudoprogression may occur in patients with BM 
treated with immunotherapy using checkpoint inhibitors such as CTLA-4 (cytotoxic T 
lymphocyte-associated antigen 4; e.g., ipilimumab) and PD-1 (programmed cell death 
1 receptor; e.g., pembrolizumab or nivolumab) inhibitors 11,12,92,93. A pilot study showed 
the potential of FET PET to identify pseudoprogression in patients with BM originating 
from melanoma treated with immune checkpoint inhibitors 94. Data on FDG PET for 
this indication are currently not available. 
 
 At present, there is limited evidence of the potential benefit of amino acid PET 
for differentiating pseudoprogression from true disease progression following 
checkpoint inhibitor blockade (evidence level 3). 
 
 
Assessment of Treatment Response  
As stated above, standard MRI is limited in its ability to differentiate BM relapse from 
treatment-related effects such as radionecrosis or pseudoprogression, all of which can 
induce contrast enhancement and T2/FLAIR hyperintensity. The use of FDG as a 
tracer for the assessment of treatment response in PET imaging is hampered by high 
physiologic brain uptake, limiting the discrimination between tumor and normal brain 
metabolic activity 14. Furthermore, in light of newer systemic treatment options such as 
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targeted therapy and immunotherapy, tools which provide additional information on 
cellular physiology (e.g., metabolism, proliferation) have become increasingly useful. 
 
The PET tracer FLT is an analog to the nucleoside thymidine and was developed as a 
PET agent to assess cellular proliferation by tracking the thymidine salvage pathway 
95.  Recently, FLT has been applied to assess response to the chemotherapeutic agent 
ANG1005 (a drug conjugate consisting of paclitaxel covalently linked to Angiopep-2, 
designed to cross the blood-brain barrier) in patients with BM originating from breast 
cancer and was found to supplement the information derived from contrast-enhanced 
MRI by clarifying equivocal MRI findings 50. 
 
In BM from malignant melanoma being treated with targeted therapy and 
immunotherapy, a small study found in a subset of patients that metabolic responders 
may show a proliferative reduction on FLT PET despite apparent morphologic 
progression on standard MRI (i.e., pseudoprogression) 54. 
 
Studies evaluating amino acid PET for the assessment of treatment response are 
lacking. Theoretically, amino acid PET has the potential to add valuable information to 
standard MRI for the assessment of treatment response; validation in clinical studies 
is required. An illustrative example for this potential indication is presented in Figure 3. 
 
 Currently only preliminary evidence exists for a potential benefit of PET for the 








CURRENT LIMITATIONS AND FUTURE PERSPECTIVE  
 
At present, the differentiation of radiation injury from BM recurrence using amino acid 
PET has been the most thoroughly investigated indication (Table 3), repeatedly 
demonstrating high diagnostic accuracy. However, it should be noted that these data 
were derived mainly from retrospective analyses performed in single centers, and 
diagnoses were not consistently confirmed histologically. Prospective multicenter 
studies are therefore needed to validate initial results of these proof-of-principle 
investigations. Challenges of prospective validation are several, including 
heterogeneity of patient population, i.e., various originating cancers, number of BMs, 
and varying treatment regimens. Amino acid PET tracer availability and cost present 
additional obstacles. 
 
Contrary to gliomas and transosseous meningiomas, the majority of BM can be easily 
delineated by conventional MRI. Thus, PET imaging does not add significant additional 
information. Detecting multiple, small BM remains a major clinical challenge, potentially 
impacting not only prognosis, but also treatment (i.e., a shift from local treatment such 
as surgery or SRS to WBRT or systemic treatment options). Due to the limited spatial 
resolution of PET, miliary disseminated metastatic disease or leptomeningeal 
metastasis is challenging to assess and may be unapparent by current PET imaging. 
The still frequent use of FDG PET in the brain is of limited value due to poor lesion-to-
background contrast, partially explaining disappointing results in screened cohorts 96. 
New PET tracers, e.g., TSPO, might help to overcome this problem 97 and may 




PET imaging in meningiomas using specific somatostatin receptor ligands such as 
68Ga-DOTATATE PET has shown that tracer uptake may correlate with tumor grade 
as well as the likelihood of response to specific radionucleotide therapy 98,99. Intra-
individual variation in patients with multiple lesions has been noted 100. By analogy, 
further investigations should aim to non-invasively image intra-individual heterogeneity 
in patients with multiple BM. Optimal patient management may benefit by improved 
and well-validated prognostic and predictive imaging markers derived from PET, as by 
the identification and quantification of target molecules for specific therapy, e.g., EGFR 
101-103. Moreover, this could lead to early response markers of successful treatment 
that can be determined prior to changes in tumor size. Lastly, more specific PET 
tracers could potentially better identify BM primary cancer of origin.  
 
By altering radioisotopes, PET ligands initially used for diagnostic imaging might also 
be instrumental for therapy. This concept of “theranostics” has already been introduced 
into the management of prostate cancer 104-106. Moreover, PET might help in the future 
to identify drug delivery into tumor tissue and provide imaging-based data on inter- and 
intra-individual variability of tumor drug concentration, thereby permitting more relevant 
information for patient selection and therapy tailoring 107,108. 
 
Another methodological innovation which could advance research in patients with BM 
is the increasing availability of hybrid PET/MR scanners, allowing the simultaneous 
acquisition of both imaging modalities. For example, the acquisition of dynamic FET 
PET, contrast-enhanced structural and perfusion-weighted MRI, and other advanced 
MRI sequences such as MR spectroscopy and functional MRI in a single session 
(“one-stop shop”) can now be performed. Besides optimizing co-registration of various 
imaging modalities, this technology appears particularly attractive for BM patients with 
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poor clinical condition by considerably reducing scanning time and avoiding exposure 
to additional radiation dose associated with a PET/CT scan. From a research 
perspective, hybrid PET/MR technology provides a convenient platform for 
comparative imaging studies using amino acid PET and advanced MR imaging, ideally 
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Figure 1: 56-year old female patient with a brain metastasis originating from a papillary 
thyroid carcinoma treated with radiosurgery. Follow-up MR imaging 15 months later 
(top row, left) is consistent with stable disease according to RANO criteria for brain 
metastases. Most probably due to the lesion size, the corresponding FDG PET (top 
row, right) shows no increased metabolic activity. During the next 12 months, the size 
of contrast enhancement increased marginally (bottom row, left). Notwithstanding the 
small lesion size on anatomical MRI, the corresponding FDOPA PET (bottom row, 
right) shows clearly increased metabolic activity indicating brain metastasis relapse. 
 
Figure 2: 50-year old female patient with a brain metastasis secondary to non-small 
cell lung cancer underwent hybrid PET/MR imaging. Six months after stereotactic 
radiosurgery, MRI suggests tumor recurrence. In contrast, FET PET shows no 
increased metabolic activity (TBRmean = 1.3), and the time-activity curve shows a 
steadily increasing FET uptake, indicating radiation injury. The diagnosis was 
confirmed by subsequent hybrid PET/MR imaging 3 months later demonstrating 
improvement of imaging findings without a therapeutic intervention. 
 
Figure 3: 45-year old female patient with a brain metastasis secondary to a BRAF-
mutated malignant melanoma treated with dabrafenib and trametinib. Comparison of 
contrast-enhanced MR and FET PET images at baseline (left column) and follow-up 
eight weeks later (right column). At follow-up, a clear decrease of the tumor/brain ratios 
(-35%) is observed whereas the MRI shows no significant change of both the contrast 
enhancement and FLAIR signal defined as stable disease according to RANO criteria 
for brain metastases. The metabolic response was associated with an overall survival 
of 9 months after treatment initiation. 




Chao et al., 
2001 109 
Belohlavek et al., 
2003 110 
Chernov et 
al., 2005 75 
Horky et al., 2011 72 Lai et al., 2015 74 
Hatzoglou et al., 
2016 76 
Tomura et al., 2017 73 
n Patients 32 25 9 25 14 24 15 
n Lesions 36 57 9 27 14 26 18 
n recurrent metastases 18 8 4 16 6 11 10 
n radiation-induced changes 18 49 5 11 8 15 8 
Histological confirmation of 
diagnosis 
36% 5% 56% n.a. 100% 23% 56% 
FDG PET 
method 
20 min static 
scan, 
45-60 min p.i. 
15 min static scan, 
35-40 min p.i. 
n.a. 
dual phase PET; 
median time between 
early and late scan, 3.8 
h 
static scan 60 min p.i., 
scan duration n.a. 
10 min static 
scan, 
60 min p.i. 
static scan 60 min p.i., 
scan duration n.a. 
Additional imaging  
method 
no no MRS no ASL DCE PWI 
DWI 
MET PET 
Sensitivity 65% 75% 50% 95% 83% 82% 40% 
Specificity 80% 94% 80% 100% 75% 80% 50% 
Accuracy n.a. 91% 67% 96% 79% n.a. n.a. 
Threshold (TBRmean) visually visually visually 
change of L/GM ratios > 
0.19 over time 
3.0 (SUVmax) 1.4 (TBRmax) 0.97 (TBRmax) 
Performance of FDG PET 
compared to another 
imaging method(s) 
n.a. n.a. inferior n.a. inferior inferior inferior 
 
ASL = arterial spin labeling; DCE PWI = dynamic contrast-enhanced perfusion-weighted imaging; DWI = diffusion-weighted imaging; 
FDG = 18F-2-fluoro-2-deoxy-D-glucose; L/GM = lesion to gray matter ratio; MET = 11C-methyl-L-methionine; n = number; n.a. = not 
available; MRS = single- and multi-voxel proton MR spectroscopy; p.i. = post-injection; TBRmean/max = mean or maximum standardized 
uptake value of the lesion divided by the maximum standardized uptake value of the reference region; SUVmax = maximum standardized 
uptake value 
Table





et al., 2003 78 
Terakawa et 
al., 2008 77 
Galldiks et al., 
2012 35 
Lizarraga et 
al., 2014 80 
Cicone et 
al., 2015 81 
Minamimoto  
et al., 2015 79 
Romagna et al., 
2016 37 
Ceccon et al.,  
2017 36 





n Patients 21 51 31 32 42 39 22 62 15 32 
n Lesions 21 56 40 83 46 42 50 76 18 37 
n recurrent metastases 9 24 19 32 20 n.a. 21 36 10 19 
n radiation-induced 
changes 




52% n.a. 28% 11% 24% n.a. 40% 34% 56% 46% 
Tracer MET MET FET FDOPA FDOPA MET FET FET MET MET 
Amino acid PET 
method 
10 min static 
scan, 
20 min p.i. 
10 min static 
scan, 
20 min p.i. 
dynamic scan, 
0-50 min, 16 
frames, 
summed image 
20-40 min p.i. 
20 min static 
scan, 




15 min p.i. 
10 min static 
scan, 
20 min p.i. 
dynamic scan, 
0-40 min, 16 
frames, summed 
image 10-30 min 
p.i. 
dynamic scan, 
0-50 min, 16 
frames, 
summed images 
20-40 min p.i. 
static scan 20 





20 min p.i. 
Additional imaging  
method 




Sensitivity 78% 79% 74% 81% 90% 82% 86% 86% 90% 82% 
Specificity 100% 75% 90% 73% 92% 86% 79% 88% 75% 75% 
Accuracy n.a. n.a. 83% 76% 91% 83% 82% 87% n.a. n.a. 
Threshold (TBRmean) 1.4 1.4 2.0 1.7 
1.6 
(TBRmax) 
1.3 (TBRmax) 2.0 2.0 1.4 (TBRmax) 
1.4 
(TBRmax) 
Increase of accuracy by 
integrating dynamic 
FET PET parameters 
n.a. n.a. 10% n.a. n.a. n.a. 6% 1% n.a. n.a. 
Performance of amino 
acid PET compared to 
another imaging 
method(s) 
n.a. n.a. n.a. n.a. superior n.a. n.a. n.a. superior n.a. 
 
DSC PWI = dynamic susceptibility contrast-enhanced perfusion-weighted imaging; DWI = diffusion-weighted imaging; FDG = 18F-2-
fluoro-2-deoxy-D-glucose; FDOPA = 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine; FET = O-(2-[18F]fluoroethyl)-L-tyrosine; L/GM = 
lesion to gray matter ratio; MET = 11C-methyl-L-methionine; n = number; n.a. = not available; p.i. = post-injection; TBRmean/max = mean 
























Table 3: Summary of recommendations  
 
 
Amino acid PET  











(++) - n.a. 3 
Differential 
diagnosis of newly 
diagnosed BM 
(++) - n.a. 3 
Differentiation of 
radiation-induced 
changes from BM 
recurrence 










(++) n.a. (++) 3 
 
++ high diagnostic accuracy; (++) high diagnostic accuracy, but limited data available; 
+  limited diagnostic accuracy; - not helpful; n.a. = only preliminary or no data available; 
*increased accuracy when using dynamic FET PET 
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